Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRONASDAQ:MRUSNASDAQ:OCSNYSE:OGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$52.01+0.3%$48.88$21.02▼$58.40$4.13B-0.151.05 million shs404,821 shsMRUSMerus$53.84+1.0%$49.89$33.19▼$62.98$3.73B1738,077 shs222,443 shsOCSOculis$18.96-1.1%$18.89$10.79▼$23.08$829.59M0.2945,369 shs8,545 shsOGNOrganon & Co.$10.08-0.7%$9.61$8.01▼$23.10$2.59B0.63.54 million shs2.38 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics+0.26%-7.58%+0.78%+41.61%+137.18%MRUSMerus+0.96%+1.24%-13.75%+41.28%+1.68%OCSOculis-1.07%-2.70%-2.49%+22.29%+62.01%OGNOrganon & Co.-0.84%+0.88%+6.78%-22.71%-50.42%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKROAkero Therapeutics3.5687 of 5 stars3.51.00.04.71.80.80.0MRUSMerus1.8669 of 5 stars3.61.00.00.01.42.50.0OCSOculis1.7686 of 5 stars3.53.00.00.00.60.00.6OGNOrganon & Co.4.8251 of 5 stars3.34.01.73.71.73.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 3.00Buy$82.5058.61% UpsideMRUSMerus 3.14Buy$84.6457.20% UpsideOCSOculis 3.00Buy$35.3386.41% UpsideOGNOrganon & Co. 2.50Moderate Buy$18.0078.66% UpsideCurrent Analyst Ratings BreakdownLatest OCS, AKRO, MRUS, and OGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025AKROAkero TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$63.00 ➝ $64.005/23/2025MRUSMerusBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$96.00 ➝ $110.005/22/2025OGNOrganon & Co.BNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/19/2025MRUSMerusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $75.005/15/2025OGNOrganon & Co.Piper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$24.00 ➝ $18.005/13/2025AKROAkero TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $78.005/9/2025OCSOculisChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$28.00 ➝ $33.005/8/2025MRUSMerusWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.005/5/2025OGNOrganon & Co.Morgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$15.00 ➝ $10.005/2/2025OGNOrganon & Co.Evercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Inline4/28/2025MRUSMerusWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$10.75 per shareN/AMRUSMerus$36.13M103.13N/AN/A$9.46 per share5.69OCSOculis$780K1,060.99N/AN/A$1.91 per share9.92OGNOrganon & Co.$6.40B0.41$4.99 per share2.02$1.83 per share5.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$252.06M-$1.95N/AN/AN/AN/A-15.19%-13.97%8/8/2025 (Estimated)MRUSMerus-$215.33M-$4.08N/AN/AN/A-506.73%-35.99%-29.83%7/30/2025 (Estimated)OCSOculis-$97.43M-$2.64N/AN/AN/A-13,788.70%-92.95%-70.03%8/26/2025 (Estimated)OGNOrganon & Co.$864M$2.883.502.691.0411.92%227.43%7.34%8/5/2025 (Estimated)Latest OCS, AKRO, MRUS, and OGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MRUSMerus-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million5/12/2025Q1 2025AKROAkero Therapeutics-$1.01$0.90+$1.91$0.90N/AN/A5/8/2025Q1 2025OCSOculis-$0.51-$0.77-$0.26-$0.77$0.22 million$0.32 million5/1/2025Q1 2025OGNOrganon & Co.$0.89$1.02+$0.13$0.33$1.53 billion$1.51 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/AMRUSMerusN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.79%N/A2.78%N/ALatest OCS, AKRO, MRUS, and OGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025OGNOrganon & Co.quarterly$0.020.8%5/12/20255/12/20256/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero Therapeutics0.0316.8016.80MRUSMerusN/A5.865.86OCSOculisN/A4.794.79OGNOrganon & Co.16.491.671.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/AMRUSMerus96.14%OCSOculis22.30%OGNOrganon & Co.77.43%Insider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.07%MRUSMerus4.57%OCSOculisN/AOGNOrganon & Co.1.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3079.72 million74.08 millionOptionableMRUSMerus3769.21 million66.05 millionOptionableOCSOculis243.66 millionN/ANot OptionableOGNOrganon & Co.4,000259.96 million254.86 millionNot OptionableOCS, AKRO, MRUS, and OGN HeadlinesRecent News About These CompaniesORGANON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN2 hours ago | prnewswire.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Organon & Co. ...July 4 at 6:07 PM | gurufocus.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OGNJuly 4 at 6:04 PM | globenewswire.comOGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Organon & Co. ...July 4 at 4:31 PM | gurufocus.comOGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJuly 4 at 4:00 PM | globenewswire.comOGN SHAREHOLDERS: The Organon & Co. July 22 Class Action Deadline is Approaching -- Contact ...July 4 at 9:12 AM | gurufocus.comOGN SHAREHOLDERS: The Organon & Co. July 22 Class Action Deadline is Approaching -- Contact BFA Law if You Suffered Losses (NYSE:OGN)July 4 at 8:08 AM | globenewswire.comOrganon (OGN) Stock Dips While Market Gains: Key FactsJuly 3 at 6:51 PM | zacks.comOrganon & Co. (NYSE: OGN) Deadline Approaching: Berger Montague Advises Investors of ...July 3 at 6:09 PM | gurufocus.comOrganon & Co. (NYSE: OGN) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud LawsuitJuly 3 at 5:36 PM | prnewswire.comOrganon & Co. Sued for Securities Law Violations -- Investors Should Contact Levi & ...July 3 at 5:13 PM | gurufocus.comOrganon & Co. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – OGNJuly 3 at 4:29 PM | globenewswire.comDeadline Alert: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud LawsuitJuly 3 at 1:12 PM | globenewswire.comOGN vs. MEDP: Which Stock Is the Better Value Option?July 3 at 12:41 PM | zacks.comLost Money on Organon & Co.(OGN)? Join Class Action Suit Seeking Recovery - Contact The ...July 3 at 10:15 AM | gurufocus.comLost Money on Organon & Co.(OGN)? Join Class Action Suit Seeking Recovery - Contact The Gross Law FirmJuly 3 at 9:00 AM | prnewswire.comSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of OrganonJuly 3 at 8:25 AM | prnewswire.comKarolinska Development receives update from Organon concerning OG-6219July 3 at 2:00 AM | globenewswire.comORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGNJuly 2 at 10:13 PM | globenewswire.comThe Gross Law Firm Reminds Organon & Co. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2025 – OGNJuly 2 at 4:02 PM | globenewswire.comSippican Capital Advisors Raises Stake in Organon & Co. (NYSE:OGN)July 2 at 7:54 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOCS, AKRO, MRUS, and OGN Company DescriptionsAkero Therapeutics NASDAQ:AKRO$52.01 +0.13 (+0.26%) Closing price 07/3/2025 02:56 PM EasternExtended Trading$52.06 +0.04 (+0.08%) As of 07/3/2025 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Merus NASDAQ:MRUS$53.84 +0.51 (+0.96%) Closing price 07/3/2025 01:04 PM EasternExtended Trading$53.38 -0.46 (-0.85%) As of 07/3/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.Oculis NASDAQ:OCS$18.95 -0.21 (-1.07%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.Organon & Co. NYSE:OGN$10.07 -0.08 (-0.74%) Closing price 07/3/2025 03:56 PM EasternExtended Trading$10.06 -0.02 (-0.20%) As of 07/3/2025 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.